The partnership reflects a focus on precision oncology, seeking to enhance patient selection and assess treatment responses.

Trastuzumab pamirtecan, being developed under a 2023 partnership between BioNTech and DualityBio, elicited a 44.1% overall ...

The wave-shaped chart Ratul Chowdhury pulls up on a computer monitor in his office captures the evolutionary cat-and-mouse ...

Telix contributes end-to-end radiopharma capabilities, including isotope selection, radiochemistry, scalable manufacturing, and a global distribution network tailored to short half-life radioisotopes.

SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points (p<0.0001) from baseline at Week 12 in Robart’s ...

FairJourney Bio (FJBio), a global antibody discovery contract research organization (CRO), today announced the opening of its advanced cryo-electron microscopy (cryo-EM) structural biology facility in ...

Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing ...

Voyager Therapeutics' anti-tau monoclonal antibody VY7523 demonstrated an excellent safety and PK profile in phase 1 SAD.

A new nanodisc-based platform lets scientists study viral proteins in a form that closely mimics real viruses, revealing how ...

I initiate coverage on Forte Biosciences stock at a 'Hold' rating due to both pipeline risk and upcoming clinical catalysts.

Five vaccines in development for HIV, tuberculosis, cancer, influenza, and coronaviruses could transform global health.

Altruist Biologics secures NMPA license, expanding its Hangzhou facility to solidify its role in China's rapidly growing ...